EVEkaterina V. Verenikina

Ekaterina V. Verenikina

*This is an algorithmically generated author record based on publicly available information.

Ekaterina V. Verenikina has a total of 172 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predictive role of tumor microenvironment components and stem cell markers in vulvar squamous cell carcinoma

    by N. M. Abdullaeva, E. Y. Zlatnik, E. V. Verenikina, E. P. Ulyanova, Z. V. Verenikina, V. A. Menshenina, A. O. Adamyan, S. A. Kornienko

    Background. Vulvar cancer remains a rare but aggressive pathology with a high percentage of advanced cases at the time of diagnosis. Understanding the role of the tumor microenvironment is critically important for predicting disease progression and developing new therapeutic strategies. Aim. To evaluate the prognostic significance of expression of stemness (ALDH1, CD133), matrix remodeling (MMP-2, TIMP-2) and immunosuppression (CD68, CD206, FoxP3) markers in tumor cells and stroma of vulvar squamous cell carcinoma. Materials and methods. A retrospective immunohistochemical study was conducted on surgical specimens from 56 patients with confirmed vulvar squamous cell carcinoma (stage I: n = 20; stage II: n = 26; recurrences: n = 10). A semi-quantitative analysis of marker expression was performed, assessing associations with clinical and morphological parameters (stage, invasion depth). Results. Vulvar cancer progression (stage II, invasion 4 mm) was associated with an increase in the stem cell pool (ALDH1+ in the stroma, CD133+ in the tumor); an increase in MMP-2 expression (p = 0.01); accumulation of M2 macrophages (CD206+) and regulatory T cells (FoxP3+) in the stroma, with levels 4 times higher than in the parenchyma. Recurrences were characterized by a profile similar to early stages but with dominance of the M2 phenotype in the stroma ( 50 %) and a higher level of CD133+ expression. Conclusion. Stroma-dependent immunosuppression and stem cell activation are key drivers of vulvar cancer progression. The findings support the potential of targeted therapy directed at tumor microenvironment components.

  • Open Access

    Predictive informativeness of risk factors for the development of ovarian cancer of different histological types: a randomized study

    by Mariya Yu. Grafskaya, Ekaterina V. Verenikina, Alexandra A. Demidova, Fedor E. Filippov, Natalia V. Karasenko, Графская Мария Юрьевна

    BACKGROUND: Given the considerable morphological heterogeneity of invasive epithelial ovarian cancer, characterized by differences in clinical course and rates of progression, investigation of predictors specific to each histological type is of particular relevance. AIM: This work aimed to identify the predictive significance of hereditary and phenotypic factors modulating the risk of developing different histological types of invasive epithelial ovarian cancer. METHODS: A total of 620 patients with invasive epithelial ovarian cancer of various histological types were examined in the main group: serous carcinoma (57.7%), endometrioid carcinoma (23.1%), clear cell carcinoma (11.6%), and mucinous ovarian carcinoma (7.6%). The control group consisted of 226 women without cancer. Information on risk factors was obtained from medical records. Comparative analysis of the frequency characteristics of the studied variables between the main and control groups was performed using the Pearson chi-square (χ2) test. The strength of association was assessed using Cramér’s V coefficient. RESULTS: Compared with the control group, the main group showed higher frequencies of ovarian cancer (7.7% vs. 0%; p 0.001) and breast cancer (5.0% vs. 0%; p 0.001) in first-degree relatives; obesity in childhood (11.3% vs. 5.3%; p = 0.002), obesity in adolescence (10.6% vs. 3.5%; p = 0.001), and obesity at the time of primary diagnosis (47.1% vs. 21.7%; p 0.001). The main group more frequently reported the use of postmenopausal hormone replacement therapy (45.0% vs. 33.6%; p = 0.003) and endometriosis (13.4% vs. 7.5%; p = 0.02), whereas full-term pregnancy (p 0.001), breastfeeding (p 0.001), and oral contraceptive use (p 0.001) were less frequent. For the development of advanced serous ovarian carcinoma, the most substantial predictors were hereditary factors, obesity at the time of diagnosis, and postmenopausal hormone replacement therapy. In comparison with serous carcinoma, the distinguishing predictors were endometriosis, late menopause, and obesity in childhood and adolescence for endometrioid carcinoma; endometriosis for clear cell carcinoma; and obesity in adolescence and smoking for mucinous ovarian carcinoma. CONCLUSION: In rare histological types of invasive epithelial ovarian cancer, compared with serous carcinoma, the predictive significance of endometriosis, late menopause, smoking, and obesity in childhood and adolescence increases substantially.

  • Open Access

    Features of hereditary and modifiable risk factors in ovarian cancer of different histotypes

    by M. Yu. Grafskaya, A. Yu. Maksimov, E. V. Verenikina, A. A. Demidova, F. V. Logvin, N. N. Timoshkina, F. S. Bova, М. Ю. Графская

    Purpose of the study . To identify the association between the carriage of BRCA1/2 gene mutations and the histological type of ovarian cancer, as well as morbid obesity as a risk factor. Materials and methods . The study included 635 patients with epithelial invasive ovarian cancer. The results of histological examination of surgical specimens, height and weight were analyzed. To identify mutations in the BRCA1 and BRCA2 genes, lymphocytes of venous peripheral blood and malignant tumor tissue obtained during surgery were examined. Polymorphisms of the BRCA1 and BRCA2 genes were determined at 8 points using real-time polymerase chain reaction. Results . Germinal mutations of the BRCA1/2 genes in the blood were detected in 13,5 %. In the subgroups of patients carrying mutations of the BRCA1 and BRCA2 genes, serous ovarian carcinoma was encountered in the predominant number of cases (86,7 and 81,8 % respectively). Genetic analysis of cancer cells from surgical specimens revealed mutations in the BRCA1 and BRCA2 genes in 21,9 %. In 53 women, mutations in the studied genes were detected only in the tumor tissue, but not in the blood, which allowed them to be classified as somatic. The incidence of morbid obesity among patients with spontaneous mutations (20,75 %) is higher (p=0,05) than in women with germline mutations in the BRCA1/2 genes (8,1 %). Conclusions . Germline mutations in the BRCA1 and BRCA2 genes occur in 13,5 % and are associated with the development of serous ovarian carcinoma. Morbid obesity is a risk factor for spontaneous mutations in repair genes.

  • Open Access

    Prospects for the detection of ovarian cancer by genetic testing of aspirate from the uterine cavity

    by M. Yu. Grafskaya, E. V. Verenikina, A. Yu. Maksimov, A. A. Demidova, E. V. Bova, M. I. Nazheva, I. V. Dubatova, М. Ю. Графская

    In the article, a genetic study of biological samples from uterine cavity aspirate was performed in patients with serous ovarian carcinoma in order to identify gene mutations characteristic of ovarian tumor lesions. It has been proven that the aspiration from the uterine cavity contains diagnostically significant numbers of cells or fragments of ovarian cancer cells necessary for molecular genetic analysis and detection of mutations in the TP53, FAT3, CSMD3, BRAF, and KRAS genes. Mutations of the BRCA1/2 genes are rare. The detection of TP53, FAT3, CSMD3, BRAF, and KRAS gene mutations in uterine aspirate cells requires an active diagnostic search for the detection of ovarian serous carcinoma.

  • Effectiveness of adding molecular-genetic testing to liquid-based papanicolaou cytology for detecting endometrial cancer in women with comorbidities

    by Mariya Yu. Grafskaya, Ekaterina V. Verenikina, Alexandra A. Demidova, Mariya V. Ermilova, Elena V. Bova

    BACKGROUND: Developing an effective screening strategy for women with morbid obesity using accessible and simple biological sampling methods remains critical. AIM: This study aimed to evaluate the effectiveness of additional molecular genetic testing of cervical canal biopsy samples in detecting endometrial cancer in women with morbid obesity. METHODS: Overall, 378 patients with endometrial cancer were examined. Two groups were formed based on comorbid status: the study group (n = 103) with morbid obesity and comparison group (n = 275) without obesity. The control group included 226 women without oncologic conditions: 47 with morbid obesity and 179 without obesity. Cervical canal samples were collected by brush biopsy. Extracted DNA was amplified using polymerase chain reaction to detect oncogenic mutations in 18 genes. RESULTS: Oncogenic mutations were identified in endocervical scrapings more frequently in the study group (82.5%; p = 0.042) than in the comparison group (72.4%). In the control group, oncogenic mutations were rare and not significantly associated with obesity (8.5% vs 3.9%; p = 0.193). In patients with endometrial cancer and morbid obesity, mutation detection increased, and the spectrum of mutated genes was broader. The most informative genes for screening were PTEN, TP53, PIK3CA, PIK3R1, CTNNB1, KRAS, FBXW7, FGFR2, APC, and POLE. CONCLUSION: Molecular testing for oncogenic mutations in cervical liquid-based cytology samples is an effective endometrial cancer screening method. The presence of morbid obesity enhances the test’s diagnostic yield and expands the range of detectable mutations.

  • Informative value of genetic testing of the biological environment obtained during Papanicolaou tests for ovarian cancer screening

    by M. Yu. Grafskaya, A. Yu. Maksimov, E. V. Verenikina, A. A. Demidova, N. N. Timoshkina, М. Ю. Графская

       Purpose of the study. To assess the informative value of genetic testing for oncogenic mutations in biological samples obtained during the Papanicolaou test for ovarian cancer screening.   Materials and methods. The study included 336 patients of the main group with verified ovarian cancer, including borderline ovarian tumors. The control group consisted of 226 patients of a similar age without oncological pathology. Patients of the main and control groups were divided into two subgroups depending on the presence of morbid obesity. Biological material from the endocervical canal was collected by brush biopsy. After standard liquid cytological examination, additional genetic testing for mutations in 18 tumor driver genes was performed using the PCR method.   Results. In morbid obesity, the frequency of oncogenic mutations of driver genes in endocervical scraping samples increased only in borderline ovarian tumors compared to patients without obesity (64 % versus 24,3 %, p = 0,002) and was similar in ovarian cancer (37,3 % versus 30,4 %, p = 0,29). Detection of driver gene mutations in endocervical smear samples with negative Pap test results for cervical cancer and human papillomavirus infection increased the risk of ovarian tumor pathology detection regardless of the presence or absence of obesity, which determines the prospects of additional genetic testing of cervical canal material. Genetic testing of endocervical samples to assess the risk of ovarian cancer can be limited to assessing the mutational status of the TP53, FGFR 2, and CTNNB 1 genes.   Conclusion. Additional genetic testing to detect mutations in driver genes in endocervical smear samples in women with morbid obesity is effective in screening for borderline ovarian tumors.

  • Open Access

    Optimizing early detection of uterine cancer in women with risk factors

    by M. Yu. Grafskaya, E. V. Verenikina, A. Yu. Maksimov, A. A. Demidova, N. V. Karasenko, M. V. Ermilova, М. Ю. Графская

    The article describes the stages of early detection of uterine body cancer in patients with morbid obesity. It has been proven that genetic testing for oncogenic mutations of endocervical canal scrapings with a negative cytological conclusion regarding cervical cancer is effective for subsequent screening of uterine body cancer. In morbid obesity, the diagnostic sensitivity of mutation screening for uterine body cancer increases when examining endocervical canal scrapings. When oncogenic mutations are detected in samples from the endocervical canal, the next step is recommended to conduct a cytological examination of endometrial biopsies with sampling using brush technology.

  • Open Access

    Free radical oxidation and antioxidant defense in uterine myoma and endometrioid adenocarcinoma depending on its degree of differentiation

    by E. I. Surikova, E. M. Frantsiyants, I. V. Kaplieva, V. A. Bandovkina, L. A. Nemashkalova, I. V. Neskubina, T. I. Moiseenko, A. P. Menshenina, M. A. Rogozin, E. V. Verenikina, et al.

    Purpose of the study. To evaluate the features of free radical oxidation (FRO) and the principal enzymatic and non-enzymatic links of antioxidant defense in proliferating tissues of benign myoma and malignant endometrioid adenocarcinoma (EA) with varying degrees of differentiation.Patients and methods. Patients who received surgical treatment for EA (n = 42) and uterine myoma (n = 14) were examined. Patients with stage Ia (n = 26) and stage Ib (n = 16) of disease were selected. 16 patients had highly differentiated (G1) EA, 12 had moderately differentiated (G2) EA, and 14 had low-differentiated (G3) EA. The activity of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione transferase (GST), reduced glutathione (GSH), vitamins A and E, lipid peroxidation products diene conjugates (DC) and malondialdehyde (MDA) were determined colorimetrically in the tissues of EA, myoma and intact uterus.Results. Compared with the level in intact tissue, SOD decreased by 3.2 times and GST increased by 2.7 times in myoma (p < 0.01). Similar changes were noted for EA G1 – on average by 5.3 times (p < 0.01) and also DC increased by 2.2 times (p < 0.05). In EA G2 tissue, SOD and GPx activities were lower than in the intact tissue, by 5.7 and 4.5 times, respectively (p < 0.05), and lower GST, GPx and GSH than in the EA G1, by 4.9, 8.9 and 1.6 times, respectively (p < 0.05 – p < 0.01). In EA G3 tissue, there was an increase in GSH, GPx and GST from 1.5 to 7.1 times (p < 0.05 – p < 0.01) and lipid peroxidation products by an average of 2.5 times (p < 0.05), as well as a decrease in vitamins A and E by 2.9 and 4.6 times, respectively (p < 0.05) compared with the intact tissue. The tissue of the EA G2 had a minimal level of activity of the GSH-dependent system.Conclusion. The results reflect the differences in the mechanisms of proliferation regulation by FRO in myomas and in the EA tissue with changes in its differentiation. Knowledge of the characteristics of individual links in the regulation of FRO can play a certain role in the use of antioxidant therapy for benign or malignant tumors of the uterus.


  • Open Access

    LOCAL IMMUNE STATUS IN DIFFERENT CLINICAL COURSE OF ENDOMETRIAL CANCER

    by V.V. Polovodova, A.B. Sagakyants, E.S. Bondarenko, E.V. Verenikina, O.G. Shulgina, K.M. Zakaryan, N.A. Maksimova, A.A. Cherkasova, V.M. Zhenilo